HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Sutro Biopharma (NASDAQ:STRO) and maintained a $16 price target for the company's stock.
November 14, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reaffirmed a Buy rating on Sutro Biopharma and kept the price target at $16.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price. The direct mention of the company and the specific price target provides a clear and bullish signal to the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100